title: The preventive effects of G115 on balloon injury-induced neointima formation in rats.
abstract: After percutaneous transluminal coronary angioplasty (PTCA), 30-50% of the patients may present with restenosis within 6 months. The aim of this study was to search for a preventive remedy against the balloon injury-induced neointima formation. Ginseng, with its wide indications on immune and cardiovascular functions, has prompted us to explore its role in neointima formation. In the present study, we aimed to explore if a standardized Panax Ginseng extract G115 was able to inhibit neointimal formation. With BrdU luminencence assay, maximal proliferation of rat smooth muscle cells was reduced to 24% of control values by G115. Norepinephrine-induced vasocontraction was antagonized in 21% and 44% by 1.44mg/ml and 2.88mg/ml of G115, respectively. Neointima-to-lumen area ratio of balloon-injured rat carotid arteries was reduced 77.3% by G115 as compared to the sham control. These results demonstrate the preventive effects of ginsenosides on angioplasty-mediated neointima formation.
authors.affiliation: Department of Pharmacology, School of Medicine, China Medical College, Taichung, Taiwan.
authors.forename: C H
authors.initials: CH
authors.lastname: Wu
authors.forename: B R
authors.initials: BR
authors.lastname: Tsai
authors.forename: W T
authors.initials: WT
authors.lastname: Hsieh
authors.forename: G Y
authors.initials: GY
authors.lastname: Chang
authors.forename: S J
authors.initials: SJ
authors.lastname: Mao
authors.forename: W C
authors.initials: WC
authors.lastname: Chang
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002851:Chromatography, High Pressure Liquid; D023903:Coronary Restenosis / Q000517:prevention & control*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D036145:Ginsenosides; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007118:Immunoassay; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D009638:Norepinephrine / Q000494:pharmacology; D005894:Panax; D051381:Rats; D017207:Rats, Sprague-Dawley; D012503:Saponins / Q000627:therapeutic use*; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology
chemical_list: D036145:Ginsenosides; D000960:Hypolipidemic Agents; D012503:Saponins; D009638:Norepinephrine